New Pharmaceutical Formulations for Personalized Therapies

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmaceutical Technology, Manufacturing and Devices".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 1713

Special Issue Editor


E-Mail Website
Guest Editor
Institute of Cardiology, Medical Academy, Lithuanian University of Health Sciences, Sukilėlių g. 15, LT-50009 Kaunas, Lithuania
Interests: pharmacogenomics; precision medicine; antiplatelets; anticoagulants; drug metabolism

Special Issue Information

Dear Colleagues,

Precision (personalized) medicine is increasingly becoming more precise, accurate, and influential for tailoring the right drug for the right patient today. In recent years, discoveries and developments in the pharmaceutical industry have led to improvements in available drugs and their formulations and have also paved the way to new treatments. The emergence of adverse drug reactions, drug resistance, errors of drug formulations, and pharmacogenomic profiles are the issues that may be overcome using tailored therapy. Nanotechnologies, targeted drug delivery, and 3D printing for preparation of pharmaceutical formulations will help to meet the individual needs of patients. New technologies for the production of drugs will be of huge importance in critical situations.

The aim of this article collection is to contribute to advancements in the field of development and perspectives of precision drug formulations.

Dr. Vacis Tatarūnas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacogenomics in pharmaceutical formulations
  • tailored pharmaceuticals
  • precision pharmaceuticals
  • 3D printing and precision medicine
  • nanomaterials for tailored drugs
  • personalized drug formulations
  • targeted drug delivery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 1856 KiB  
Review
Precise Therapy Using the Selective Endogenous Encapsidation for Cellular Delivery Vector System
by Vacis Tatarūnas, Ieva Čiapienė and Agnė Giedraitienė
Pharmaceutics 2024, 16(2), 292; https://doi.org/10.3390/pharmaceutics16020292 - 19 Feb 2024
Viewed by 1073
Abstract
Interindividual variability in drug response is a major problem in the prescription of pharmacological treatments. The therapeutic effect of drugs can be influenced by human genes. Pharmacogenomic guidelines for individualization of treatment have been validated and used for conventional dosage forms. However, drugs [...] Read more.
Interindividual variability in drug response is a major problem in the prescription of pharmacological treatments. The therapeutic effect of drugs can be influenced by human genes. Pharmacogenomic guidelines for individualization of treatment have been validated and used for conventional dosage forms. However, drugs can often target non-specific areas and produce both desired and undesired pharmacological effects. The use of nanoparticles, liposomes, or other available forms for drug formulation could help to overcome the latter problem. Virus-like particles based on retroviruses could be a potential envelope for safe and efficient drug formulations. Human endogenous retroviruses would make it possible to overcome the host immune response and deliver drugs to the desired target. PEG10 is a promising candidate that can bind to mRNA because it is secreted like an enveloped virus-like extracellular vesicle. PEG10 is a retrotransposon-derived gene that has been domesticated. Therefore, formulations with PEG10 may have a lower immunogenicity. The use of existing knowledge can lead to the development of suitable drug formulations for the precise treatment of individual diseases. Full article
(This article belongs to the Special Issue New Pharmaceutical Formulations for Personalized Therapies)
Show Figures

Figure 1

Back to TopTop